With healthcare organizations digitally transforming their processes, there is an acute need for data enrichment and curation to fill the gaps, bottlenecks, and delays created by poor data movement and quality. It’s important to implement actionable insights from the available data. As part of the evolution, organizations need to revamp the data integration layer to improve data practices and enhance the quality of data, facilitating the life sciences industry to make strategic decisions supported by analytics and data-driven insights.
The growing data dependency has put the spotlight on the need to refine, enrich, and curate data to extract the best insights and evidence from real-world data. And access to clean, robust data is a necessity to attain this goal. It facilitates drawing detailed conclusions for speedy drug development and medical innovations.
The real-world data (RWD) not only provides evidence for critical clinical decisions but also generates real-world insights that expand the industry perspective on the effective use of medicine. Amidst the increasing costs and complex clinical development processes, the real-world data (RWD), with advanced analytics, is proving its mettle as a powerful enabler for transforming the drug and clinical development lifecycle.
Real-World Data: Impacting the Healthcare Environment
The simultaneous use of RWD and predictive modeling has the potential to improve clinical development and operational processes that rely heavily on historical experience and assumptions. The prevalent adoption of RWE is also augmenting the information healthcare providers’ use for clinical decision making by adding information that is not collected as part of RCTs, including unrepresented patients with chronic illnesses, diverse population groups, and the elderly.
Real-world studies have heavily contributed to attaining the fundamental goal of advancing patient care through precision while minimizing the risks. RWD facilitates drawing insights before and after the market authorization of a new drug, assess the pharmacoeconomic properties of treatment, and explores the effectiveness in conditional reimbursement schemes in the new age of medicine aided by technology.
To learn more about the scope of RWD and predictive modeling in Life Sciences, get a demo.
For more updates, subscribe to our newsletter.